What are the opening hours?

Monday 7am - 7pm Tuesday 7am - 7pm Wednesday 7am - 7pm Thursday 7am - 7pm Friday 7am - 7pm

Caris Life Sciences

Home
United States
Irving, TX
Caris Life Sciences

Caris Life Sciences delivers technologies to revolutionize healthcare with market-leading profiling

Caris Life Sciences® is the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced artificial intelligence (AI) and machine learning algorithms, Caris has created the large-scale, clinico-genomic database and computing capability needed to analyze and unravel the molecular complexity of disease. This convergence of sequencing power, big data and AI technologies provides an unmatched platform to deliver the next-generation of precision medicine tools for early detection, diagnosis, monitoring, therapy selection and drug development.

10/31/2025

Join us during World ADC for our poster presentation, "Identification and Validation of Next Generation ADC Candidates from Molecularly Profiled Patient Tissue." Stop by to learn more about the research. bit.ly/4n99ZRg

10/29/2025

Caris announces collaborative new research identifying TET2 clonal hematopoiesis (CH) as a promising biomarker for improved response to immune checkpoint inhibitor (ICI) therapy in patients with solid tumors.

"These findings represent a major step forward in understanding how clonal hematopoiesis influences cancer immunology," said Milan Radovich, Ph.D., Senior Vice President, Chief Scientific Officer at Caris. "It further demonstrates that we are only scratching the surface on the potential applications of CH, namely a novel function of CH as a predictive therapeutic biomarker that can be used to improve patient outcomes.”

Learn more: https://ow.ly/mgFw50Xjw3M

10/27/2025

Attending World ADC in San Diego? Join Caris SVP & Chief Scientific Officer Dr. Milan Radovich, who will discuss how innovative proteomic platforms are uncovering masked targets and enabling the identification of high-confidence novel targets. He will also explore modality-agnostic strategies for validating ADC and other targets across indications, supported by multimodal insights from ~500K molecularly profiled tissue samples. https://bit.ly/4n99ZRg

10/24/2025

Caris Life Sciences will attend the World ADC 2025 Conference in San Diego, California. Meet with our team to learn how Caris Discovery is redefining novel target identification by bringing world-class science to the vast Caris tissue repository. Schedule a meeting: https://bit.ly/4n99ZRg

10/23/2025

Caris Life Sciences will report third quarter 2025 financial results on Wednesday, November 5, 2025.
Learn more: https://ow.ly/Pzvp50XgF5I

10/21/2025

Meet Jeanine Cervoni, a breast cancer survivor and advocate for awareness. With the support of Caris Life Sciences' innovative testing, she gained a deeper understanding of her cancer and made informed treatment choices. Her journey highlights the importance of personalized care.

We observe Breast Cancer Awareness Month this October and advocate for tailored treatment solutions.

Learn more: https://ow.ly/7lFk50Xffsk

10/19/2025

ESMO 2025 is underway. Stop by Booth 1007 to meet with the Caris Life Sciences team and explore how our molecular profiling and AI-driven insights are shaping the future of oncology. We’re ready to connect: https://bit.ly/4mFl38k

10/14/2025

Caris and collaborators within the Caris Precision Oncology Alliance (Caris POA) will collectively present six studies across nine tumor types at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, in Berlin, Germany from October 17-21, 2025.

“By integrating real-world data, advanced sequencing and biomarker discovery, we’re refining cancer subtyping and treatment decisions to improve patient outcomes across numerous cancer types,” said Milan Radovich, PhD, Senior Vice President and Chief Scientific Officer at Caris.

Learn more: https://ow.ly/khU450XaJpx

10/13/2025

At Caris, we’re committed to providing valuable information and supporting patients throughout their cancer journey. In recognition of Breast Cancer Awareness Month, Chief Medical Officer, Dr. George Sledge, Jr., shares the top three things a patient should do when diagnosed with breast cancer.

Watch for valuable advice and learn how Caris supports patients through comprehensive molecular profiling: https://bit.ly/44yVbFv

10/08/2025

Caris Assure is an advanced assay that analyzes over 23,000+ genes at the DNA and RNA level, using whole exome and whole transcriptome sequencing. This approach offers exceptional accuracy and precision in evaluating crucial molecular features of a patient's cancer. Find out how Caris has transformed liquid biopsy profiling: https://bit.ly/4eYqHQO

10/06/2025

Join Caris Life Sciences at ESMO 2025 in Berlin. We're excited to connect with oncology leaders and share how our precision medicine innovations are advancing cancer care. Visit us at Booth 1007: https://bit.ly/4mFl38k

10/03/2025

MI Cancer Seek is an FDA-approved companion diagnostic to detect PIK3CA mutations in breast cancers to help guide treatment. This WES/WTS assay enables clinicians to identify patients most likely to benefit from targeted therapy. Learn how MI Cancer Seek supports breast cancer care: https://bit.ly/4lyGNTR

Address

-
Irving, TX
75039

Opening Hours

Monday	7am - 7pm
Tuesday	7am - 7pm
Wednesday	7am - 7pm
Thursday	7am - 7pm
Friday	7am - 7pm

Telephone

+18889798669

Website

https://www.carislifesciences.com/

Alerts

Be the first to know and let us send you an email when Caris Life Sciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Psych Dimensions

Want your practice to be the top-listed Clinic in Irving?

#WeAreCarisLS

We believe in more treatment options. Because more treatment options, can mean more time with the ones you love the most.

We’re dedicated to fulfilling the promise of precision medicine and changing the face of cancer care by providing the personalized and precise information needed to guide individualized treatment options. Learn more about our suite of market-leading molecular profiling offerings that assesses DNA, RNA and proteins to reveal the highest quality molecular blueprint so you can determine treatment options with confidence: www.carismolecularintelligence.com.